Drugs / 64Cu-FBP8
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04022915 | May 2019 → Jul 2022 | pulmonary embolism, venous thromboembolism | Peter Caravan | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03830320 | Apr 2016 → Jan 2027 expected | COVID-19, atrial fibrillation, cancer, thrombotic disease | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05336695 | Mar 2022 → Sep 2026 overdue | Alzheimer disease | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07560306 | May 2026 → Mar 2027 expected | amyloidosis | Brigham and Women's Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64CU-FBP8 | “In this study, we will use the novel fibrin-specific probe 64CU-FBP8 (Copper-64 labeled fibrin binding probe 8) for PET imaging of fresh blood clots in PE and DVT.” NCT04022915 ↗ |
| Known as | Copper-64 labeled fibrin binding probe 8 | “In this study, we will use the novel fibrin-specific probe 64CU-FBP8 (Copper-64 labeled fibrin binding probe 8) for PET imaging of fresh blood clots in PE and DVT.” NCT04022915 ↗ |
| Modality | Diagnostic / imaging agent | “a fibrin-binding radiotracer, [64Cu]FBP8” PMID 34656469 ↗ Oct 2021 |
| Route | Intravenous | “Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center” NCT05336695 ↗ |